Cargando…
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
BACKGROUND: The purpose of the present study was to explore novel biomarkers that can predict the clinical outcome of patients before treatment or during vaccination. These would be useful for the selection of appropriate patients who would be expected to exhibit better treatment outcomes from vacci...
Autores principales: | Shindo, Yoshitaro, Hazama, Shoichi, Suzuki, Nobuaki, Iguchi, Haruo, Uesugi, Kazuhiro, Tanaka, Hiroaki, Aruga, Atsushi, Hatori, Takashi, Ishizaki, Hidenobu, Umeda, Yuzo, Fujiwara, Toshiyoshi, Ikemoto, Tetsuya, Shimada, Mitsuo, Yoshimatsu, Kazuhiko, Takenouchi, Hiroko, Matsui, Hiroto, Kanekiyo, Shinsuke, Iida, Michihisa, Koki, Yasunobu, Arima, Hideki, Furukawa, Hiroyuki, Ueno, Tomio, Yoshino, Shigefumi, Fujita, Tomonobu, Kawakami, Yutaka, Nakamura, Yusuke, Oka, Masaaki, Nagano, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329922/ https://www.ncbi.nlm.nih.gov/pubmed/28241889 http://dx.doi.org/10.1186/s13046-017-0509-1 |
Ejemplares similares
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study
por: Suzuki, Nobuaki, et al.
Publicado: (2016) -
Efficacy of intraoperative recurrent laryngeal neuromonitoring during surgery for esophageal cancer
por: Takeda, Shigeru, et al.
Publicado: (2020) -
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy
por: Matsui, Hiroto, et al.
Publicado: (2017) -
Novel Biomarkers for Personalized Cancer Immunotherapy
por: Shindo, Yoshitaro, et al.
Publicado: (2019) -
A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer
por: Suzuki, Nobuaki, et al.
Publicado: (2014)